Trial Profile
Titration Target for Chinese Type 2 Diabetes Mellitus Patients Using Insulin Glargine to Achieve Glycaemic Goals: An Assessment of Three Different Fasting Plasma Glucose Targets - BEYOND III/FPG GOAL Study
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 25 Apr 2022
Price :
$35
*
At a glance
- Drugs Insulin glargine (Primary)
- Indications Type 2 diabetes mellitus
- Focus Therapeutic Use
- Acronyms BEYOND III/FPG GOAL; FPG GOAL
- Sponsors Sanofi
- 16 Apr 2022 Results of post hoc analysis assessing extent and risk of factors of residual hyperglycaemia published in the Advances in Therapy.
- 10 Nov 2021 Primary endpoint has been met (Percentage of patients with HbA1c 7% achievement) , according to results published in the Advances in Therapy
- 10 Nov 2021 Results of post-hoc analysis assessing relationship between glycemic variability and fasting plasma glucose targets used to achieve glycated hemoglobin and HbA1c levels after 24 weeks of treatment with insulin glargine and oral antidiabetic drugs published in the Advances in Therapy